Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$1.08
-$0.11(-9.46%)
At close: 4:00 PM EST
$1.08
-$0.11(-9.46%)
Day’s Range― - ―
52-Week Range$0.56 - $2.58
Previous Close$1.04
Volume669.05K
Average Volume (3M)152.12K
Market Cap
$12.66M
Enterprise Value$21.84M
Total Cash (Recent Filing)$12.91M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 19, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap1.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-50.66
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$3.33Price Target Upside208.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: PMA Submission For VCLASSubmitting a PMA marks a structural advancement from investigational to potential commercial product. Supported by Breakthrough Device status, the PMA creates a clear regulatory pathway that, if approved, enables market access, reimbursement discussions, and durable revenue potential in specialized EP labs.
Strong Pivotal Clinical Outcomes (FULCRUM‑VT)Robust pivotal results demonstrating high acute success, low major adverse events and meaningful reductions in ICD shocks underpin clinical adoption. Durable clinical evidence reduces adoption friction, supports guideline inclusion and physician trust—key for sustained procedure volume and device uptake.
Focused Product-market Fit; Potential First Purpose-built VT SystemHaving a purpose-built system targeting a defined $5.8B VT market provides a durable competitive niche. A differentiated device and ULTA-based endocardial approach can create barriers to entry, enable focused commercial efforts, and capture specialist procedures rather than competing in commoditized EP segments.
Bears Say
Minimal Revenue And Persistent Net LossesThe company lacks meaningful product revenue and remains loss-making at scale. Persistent large losses relative to negligible sales indicate the business is not yet operating sustainably; this structural profitability gap increases reliance on external funding and raises execution risk through commercialization.
Sustained Negative Operating Cash Flow And Cash BurnConsistent negative operating and free cash flow show the company is not self-funding growth. Even with improvement, ongoing cash burn requires regular financing, dilutes shareholder value over time, and constrains investments in sales, manufacturing scale-up, and post‑market studies needed for durable commercial traction.
Rising Leverage And Nasdaq Listing RiskDebt-to-equity has increased sharply (TTM ~4.21) while shares face Nasdaq bid‑price noncompliance, creating dual structural risks: heavier leverage limits financial flexibility and a potential reverse split or delisting could disrupt capital access and investor base, complicating long‑term funding and operations.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.56 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $12.66M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is Aug 19, 2026 which is in 38 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.02.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate is -0.31.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -1.915%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.33
▲(208.64% Upside)
Technical Analysis
Ownership Overview
45.47% Insiders
0.47% Mutual Funds
41.61% Other Institutional Investors
12.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---